Clinical Trial Update: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein [Phase 3]

View source ↗

Summary

Phase 3 study to assess the safety and potential efficacy of Fazirsiran for liver disease and fibrosis caused by an abnormal alpha-1 antitrypsin protein; recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Liver Fibrosis

Drugs mentioned

• Fazirsiran (fazirsiran)

Snippet

Sponsor: Takeda | Conditions: Alpha1-Antitrypsin Deficiency | Phase 3 | Status: RECRUITING